SCHEMBL18083682

SCHEMBL18083682

CC(C)(C)OC(=O)N1CCN(Cc2ccc(NC(=O)c3cccc(C(F)(F)F)c3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 4/20 0.58
▸ EPAS1 Q99814 4/20 0.58
▸ ACKR3 P25106 2/20 0.56
▸ CHRM4 P08173 1/20 0.56
▸ CHRM5 P08912 1/20 0.56
▸ CHRM1 P11229 1/20 0.56
▸ CHRM3 P20309 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ KDM4C Q9H3R0 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ RXFP1 Q9HBX9 1/20 0.53
▸ FAAH O00519 2/20 0.52
▸ MAPT P10636 1/20 0.52
▸ OPRM1 P35372 1/20 0.51
▸ OPRD1 P41143 1/20 0.51
▸ CCR2 P41597 1/20 0.51
▸ PTGS1 P23219 1/20 0.50
▸ BRAF P15056 1/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18083722 0.89 HIF1A (0.69) HIF1AEPAS1KDM4EALDH1A1FAAH
SCHEMBL8535869 0.83 FAAH (0.60) KDM4EALDH1A1RXFP1FAAHLMNA
SCHEMBL18083684 0.81 SLC2A1 (0.69) HIF1AEPAS1ACKR3CHRM4CHRM5
SCHEMBL18083681 0.81 ACKR3 (0.54) HIF1AEPAS1ACKR3RXFP1FAAH
SCHEMBL5546576 0.80 L3MBTL1 (0.62) HIF1AEPAS1KDM4EALDH1A1FAAH
SCHEMBL17066302 0.80 NPC1 (0.62) HIF1AEPAS1KDM4EALDH1A1FAAH
SCHEMBL20985396 0.80 IRAK4 (0.76) ACKR3RXFP1FAAH
SCHEMBL3258064 0.79 KDM4E (0.58) KDM4EALDH1A1RXFP1FAAHMAPT
SCHEMBL18083772 0.79 SMN1; SMN2 (0.64) HIF1AEPAS1KDM4EALDH1A1TDP1
SCHEMBL20684900 0.78 ACKR3 (0.56) HIF1AEPAS1ACKR3RXFP1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3271348-B1 NEW FYN KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2019-01-30 — — EP disclosed
US-20180111919-A1 NEW FYN KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2018-04-26 — — US disclosed
WO-2016146220-A1 NEW FYN KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2016-09-22 — — WO disclosed
EP-3070084-A1 NEW FYN KINASE INHIBITORS Rottapharm Biotech S.r.l. (IT) 2016-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111919-A1 NEW FYN KINASE INHIBITORS FYN, LCK, LYN HIF1A 2440/4885EPAS1 2013/4885ACKR3 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback